Beyond Air, Inc. · NASDAQ:XAIR
Beyond Air — Investor Presentation (August 2026)
16 slides from Beyond Air's investor presentation, August 2026
Slide 1: Corporate Presentation: Redefining Nitric Oxide Therapy
C O R P O R A T E P R E S E N TAT I O N Redefining Nitric Oxide Therapy: No Tanks, No Chemicals, Just Air. Proven Technology || Real Solution || Delivering Positive Outcomes
Slide 2: Cautionary Note Regarding Forward-Looking Statements and Disclaimers
Cautionary Note Regarding Forward-Looking Statements and Disclaimers This presentation has been prepared by Beyond Air, Inc. (“Beyond Air,” the “Company,” “we,” “us” or “our”) for informational purposes only. This presentation does not constitute an offer to sell or a solicitation of an offer to buy
Slide 3: Beyond Air is a Leader in Inhaled Nitric Oxide (iNO) Therapy
Beyond Air is a Leader in Inhaled Nitric Oxide (iNO) Therapy Category-Defining Technology No tanks, chemicals or logistics dependency. LungFit PH is currently the only tankless system that generates unlimited NO from ambient air Compelling Value Proposition We believe LungFit PH offers providers low
Slide 4: Beyond Air: The Nitric Oxide (NO) Company
Beyond Air: The Nitric Oxide (NO) Company • Disruptive, Commercial-Stage Med Device Company ✓ FDA- and CE-marked LungFit® PH in active hospital use ✓ Addressing a ~$350M U.S. and $700M+ global market today ✓ Anticipating $1B+ global NO Therapy market 1, 2 • Our Technology Advantage ✓ Generates NO fr
Slide 5: LungFit PH for the Treatment of PPHN
LungFit® PH for the Treatment of PPHN Persistent Pulmonary Hypertension of the Newborn (PPHN) is a serious respiratory condition requiring specialized neonatal respiratory support. LungFit PH delivers inhaled nitric oxide (iNO) to support oxygenation in critically ill neonates. WHAT IS PPHN Failure
Slide 6: LungFit PH II: Meaningful Advancements, Opening Up Full Market Access
LungFit PH II*: Meaningful Advancements, Opening Up Full Market Access LungFit PH II* has external transport capability which is a requirement at many large hospital systems LungFit PH LungFit PH II* Smaller. Transport Ready. Best in Class. Feature LungFit® PH LungFit® PH II 44 lbs (75 lbs on cart)
Slide 7: LungFit PH Potential Addressable Market
LungFit PH II LungFit PH Potential Addressable Market Global TAM With its new external transport capability, LungFit PH II* will expand the estimated TAM to 100% of the market. LungFit PH II US TAM ~$1B+ Current: LungFit PH US TAM ~$350M+ US + OUS Combined Estimated Opportunity upon LungFit PH II ~$
Slide 8: The Evolution of iNO Therapy
The Evolution of iNO Therapy Market is open to disruption, with significant opportunity for next-gen technology to gain market share. Disruptive Technology No Tanks. No Chemicals. Cartridge Technology Legacy Technology Tankless System Cartridge/Chemical Systems Cylinder-Based Systems Simple, efficie
Slide 9: LungFit PH: Clear Performance Advantage Across Every Key Dimension
LungFit PH: Clear Performance Advantage Across Every Key Dimension* Cylinder Systems LungFit PH II LungFit PH Genosyl (Vero) (MK, Linde, Airgas) Images Not Displayed To Scale. *Not based on head-to-head studies. 9 **The LungFit® PH II is currently under PMA review with the U.S. FDA and is not availa
Slide 10: Patented Plasma Pulse Technology
Patented Plasma Pulse Technology® LungFit® PH is the first and currently only FDA-approved and CE mark certified system to generate continuous, unlimited NO from room air 60 Watts Nitric Oxide (NO) Oxygen NO2 Smart Main and Backup Filter Generators Nitrogen Nitrogen Electrode Dioxide (NO2) 10 For il
Slide 11: Commercial Priorities
Commercial Priorities Direct US Sales Execution • Dedicated team and 1099 distributor strategy to maximize coverage and speed to market. • Maintain 90%+ customer renewal rate. GPO/IDN Access • Contracts with Vizient, Premier, HealthTrust, and Alliant, providing access to 7,000+ hospitals nationwide.
Slide 12: Pipeline Development
Pipeline Development LungFit® GO LungFit® Pro High concentration NO for at-home treatment High concentration nitric oxide in the hospital setting Priority indication is nontuberculous mycobacteria pulmonary disease (NTM-PD). Chronic, refractory lung infections such as - Pursuing Breakthrough Device
Slide 13: Financials
Financials Fiscal Year-End – March 31 (FY 2026 – April 2025-March 2026) +66% +107% - 52% Q4-26 YoY Revenue Growth, Reduction in operating FY-2026 Revenue Growth For quarter ended 3/31/26 expenses YTD (FY26 v FY24) 13
Slide 14: Financial and Patent Information
Financial and Patent Information The Company is transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026. As a result, the Company expects to report financial results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T. • 2026 Calendar ye
Slide 15: The Right Leadership Team at the Right Time
The Right Leadership Team at the Right Time to Lead Beyond Air with Our Next Generation Products Bob Carey Robert Goodman Dan Moorhead, CPA Chairman of the Board Chief Executive Officer Chief Financial Officer Mr. Carey is an experienced life sciences Mr. Goodman is a seasoned life sciences Mr. Moor
Slide 16: Thank You
THANK YOU The Mario Breathing